Media Articles Related to Reyataz (Atazanavir)
Persistent Cognitive Impairment After Perinatal HIV Infection
Source: Medscape HIV/AIDS Headlines [2016.10.13]
Cognitive impairment persists in perinatally HIV-infected children and adolescents, according to a systematic review of 22 studies, six of which were included in a meta-analysis.
Reuters Health Information
New HIV infections stagnating at 2.5 million a year worldwide
Source: HIV / AIDS News From Medical News Today [2016.07.19]
Between 2005 and 2015, rate of new HIV infections increased in 74 countries.
Study finds better definition of homelessness may help minimize HIV risk
Source: HIV / AIDS News From Medical News Today [2016.08.23]
Being homeless puts people at greater risk of HIV infection than those with stable housing, but targeting services to reduce risk behaviors is often complicated by fuzzy definitions of homelessness.
Maternal HIV status may disrupt normal microbiome development in uninfected infants
Source: HIV / AIDS News From Medical News Today [2016.07.28]
A study led by researchers at The Saban Research Institute of Children's Hospital Los Angeles (CHLA) suggests that maternal HIV infection influences the microbiome of their HIV-uninfected infants.
Published Studies Related to Reyataz (Atazanavir)
Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. [2011.09]
OBJECTIVES: Treatment of HIV/tuberculosis (TB) co-infected patients is complex due to drug-drug interactions for these chronic diseases. This study evaluates an intermittent dosing regimen for rifabutin when it is co-administered with ritonavir-boosted atazanavir... CONCLUSIONS: The benefits to HIV/TB co-infected patients receiving rifabutin 150 mg three times weekly or every other day may outweigh the risks of neutropenia observed here in non-HIV-infected subjects, provided that patients on combination therapy will be closely monitored for safety and tolerability.
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. [2011.07.15]
BACKGROUND: We compare the effect of 4 different antiretroviral regimens on limb and visceral fat... CONCLUSIONS: ABC-3TC- and TDF-FTC-based regimens increased limb and visceral fat at week 96, with a similar prevalence of lipoatrophy. Compared to the EFV group, subjects assigned to ATV-r had a trend towards higher mean percentage increase in VAT. CLINICAL TRIALS REGISTRATION: NCT00118898.
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naive HIV-1-infected patients (the ARTEN study). [2011.07]
OBJECTIVES: Dyslipidaemic effects of antiretrovirals (ARVs) may contribute to increased cardiovascular risk (CR) in HIV-1-infected patients. The ARTEN (atazanavir/ritonavir on a background of tenofovir and emtricitabine vs. nevirapine on the same background, in naive HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naive HIV-1-infected patients. Lipid profiles and CR from baseline to week 48 are reported... CONCLUSIONS: In ARV-naive patients with low CR at the outset, NVP showed a potentially less atherogenic lipid profile compared with ATZ/r. (c) 2011 British HIV Association.
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. [2011.06.15]
BACKGROUND: Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV) or atazanavir plus ritonavir (ATV/r), on bone mineral density (BMD) have not been analyzed... CONCLUSIONS: Compared with ABC-3TC, TDF-FTC-treated participants had significantly greater decreases in spine and hip BMD, whereas ATV/r led to more significant losses in spine, but not hip, BMD than EFV. Clinical Trials Registration. NCT00118898.
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. [2011.04.05]
BACKGROUND: Limited data compare once-daily options for initial therapy for HIV-1. OBJECTIVE: To compare time to virologic failure; first grade-3 or -4 sign, symptom, or laboratory abnormality (safety); and change or discontinuation of regimen (tolerability) for atazanavir plus ritonavir with efavirenz-containing initial therapy for HIV-1... CONCLUSION: Atazanavir plus ritonavir and efavirenz have similar antiviral activity when used with abacavir-lamivudine or tenofovir DF-emtricitabine. PRIMARY FUNDING SOURCE: National Institutes of Health. (c) 2011 American College of Physicians
Clinical Trials Related to Reyataz (Atazanavir)
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat [Completed]
The purpose of the study is to compare the pharmacokinetics and bioequivalence of atazanavir
in a fixed-dose combination with cobicistat with that of atazanavir coadministered with
cobicistat as single agents.
Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects [Completed]
The purpose of this study is to compare the sweetness of 2 new atazanavir powder for oral
use (POU) formulations to the current atazanavir POU in healthy participants and to select 1
atazanavir POU that has the sweetness most similar to the current atazanavir POU.
Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants [Completed]
This study assesses the effects of voriconazole, 200 mg, administered twice daily (BID), on
the steady-state pharmacokinetics of atazanavir administered as atazanavir/ritonavir,
300/100 mg once daily (QD), in healthy participants with functional CYP2C19 alleles. The
study also reviews the effects of atazanavir/ritonavir, 300/100 mg QD, on the
pharmacokinetics of voriconazole, 200 mg, BID in healthy participants with functional
Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection [Completed]
The purpose of this study is to assess the effects of famotidine, given twice daily, on
atazanavir administered with ritonavir and tenofovir in HIV-infected participants.
Phase IIB Pilot of Atazanavir + Raltegravir [Terminated]
Reports of Suspected Reyataz (Atazanavir) Side Effects
Foetal Exposure During Pregnancy (102),
Maternal Exposure During Pregnancy (66),
Abortion Spontaneous (64),
Renal Failure Acute (35),
Abortion Induced (33),
Viral Load Increased (31),
Jaundice (23), more >>